Alkermes plc. Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Alkermes plc. (ALKS) reported Interest Paid, Including Capitalized Interest, Operating and Investing Activities of $12.46 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaid · last filed 2017-02-17
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2013-03-31 was -$14.78M, a 280.71% decline year-over-year.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2012-12-31 was $3.16M, a 58.41% decline year-over-year.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2012-09-30 was $10.63M.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for the quarter ending 2012-06-30 was $8.64M.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for fiscal 2016 was $12.46M, a 1.10% increase from fiscal 2015.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for fiscal 2015 was $12.32M, a 1.33% decline from fiscal 2014.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for fiscal 2014 was $12.49M.
- Alkermes plc. interest paid, including capitalized interest, operating and investing activities for fiscal 2013 was $7.66M, a 64.65% decline from fiscal 2012.
| Period end | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 3 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 6 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 9 month | Interest Paid, Including Capitalized Interest, Operating and Investing Activities 12 month |
|---|---|---|---|---|
| 2016-12-31 | $12.46M 10-K · filed 2017-02-17 | |||
| 2015-12-31 | $12.32M 10-K · filed 2017-02-17 | |||
| 2014-12-31 | $12.49M 10-K · filed 2017-02-17 | |||
| 2013-12-31 | $9.60M 10-K · filed 2016-02-25 | |||
| 2013-03-31 | -$14.78M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$11.61M derived: sum of 2 quarters · filed 2015-02-24 | -$986.00K derived: sum of 3 quarters · filed 2015-02-24 | $7.66M 10-K · filed 2015-02-24 |
| 2012-12-31 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $13.79M derived: sum of 2 quarters · filed 2013-01-31 | $22.43M 10-Q · filed 2013-01-31 | $30.61M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | $10.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-01 | $19.27M 10-Q · filed 2012-11-01 | $27.44M derived: sum of 3 quarters · filed 2014-02-27 | $35.05M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $8.64M 10-Q · filed 2012-07-26 | $16.82M derived: sum of 2 quarters · filed 2014-02-27 | $24.42M derived: sum of 3 quarters · filed 2014-02-27 | |
| 2012-03-31 | $8.18M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $15.78M derived: sum of 2 quarters · filed 2014-02-27 | $21.66M 10-KT · filed 2014-02-27 | |
| 2011-12-31 | $7.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $13.48M 10-Q · filed 2013-01-31 | ||
| 2011-09-30 | $5.88M 10-Q · filed 2012-11-01 | |||
| 2011-03-31 | $1.68M 10-K · filed 2013-05-23 | |||
| 2010-03-31 | $4.92M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |